Ultra-low cholesterol poses no safety issues, analysis suggests

5d9cf6c8-8067-420e-ab59-562fa4b43927articleimage.jpg

29 Aug 2017 --- Aggressively reducing low-density lipoprotein cholesterol (LCL-C) to ultra-low levels poses no health risks, analysis of research has suggested. It was associated with progressively fewer cardiovascular events and no apparent safety concerns in patients with stable atherosclerotic cardiovascular disease over 2.2 years of follow-up, according to a new analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial.

The findings, presented at European Society of Cardiology (ESC) Congress on 27 August and published in The Lancet, “suggest that a lower LDL-C target – far below current guidelines – can safely be considered to further reduce the risk of recurrent cardiovascular events in high risk patients,” says investigator Dr. Robert Giugliano from Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts, US.

“These findings are unique in that they represent the first analysis of a large cohort of patients to achieve such very low LDL-C levels, namely being less than one-third of the most common treatment goal of below 1.8 millimoles per liter (mmol/L) for highest risk patients,” he says.

Lowered levels
The FOURIER trial randomized patients with stable atherosclerotic cardiovascular disease and treated with background statin therapy, to either placebo or evolocumab – a proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibody.

Initial results from the trial showed that evolocumab lowered LDL-C levels to a median of 0.8 mmol/L and significantly reduced the risk of cardiovascular events at a median follow-up of 2.2 years.

The new analysis examined efficacy and safety endpoints according to degree of LDL-C reduction at one month. In addition, a study known as EBBINGHAUS embedded within the larger analysis explored effects on cognition using a validated tablet-based tool.

A total of 25,982 patients with an LDL-C assessment at week 4 who did not experience a primary efficacy or pre-specified safety event prior to the week 4 visit were included in the analysis.

The study showed that the risk of the primary efficacy endpoint – a composite of cardiovascular death, myocardial infarction, stroke, coronary revascularization or hospitalization for unstable angina declined steadily as LDL-C levels decreased, with no significant association between LDL-C level and adverse events.

A similar reduction was observed in the key secondary endpoint, with 2,669 subjects in the lowest LDL-C category (below 0.5 mmol/L) at four weeks experiencing the lowest rate of cardiovascular death, or myocardial infarction compared to the group with highest LDL-C (above 2.6 mmol/L).

Exploratory analyses in a subgroup of 504 patients with an LDL-C lower than 0.25 mmol/L showed an even further reduction in cardiovascular events with no increase in safety events.

Additionally, among 1,154 patients who underwent formal cognitive testing prior to, or on the first day of study treatment as part of the EBBINGHAUS study, there were no adverse effects on memory, executive function, memory, or reaction time associated with lower LDL-C.

“Although longer-term follow-up will be important, the totality of evidence to date from trials of intensive lipid lowering supports reduction of LDL-C in high-risk patients to levels below those currently recommended in cholesterol guidelines,” notes Dr. Giugliano.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Health & Nutrition News

The next infant formula staple? NZMP eyes milk fat globule membrane potential

21 Nov 2018 --- As scientific understanding of infant development evolves, the industry is seeing growing opportunities for infant nutrition formulas that come as close to human breast milk as possible, and which benefit aspects such as brain and immune health. In this space, NZMP, Fonterra’s B2B ingredients business, is making strides in uncovering the potential of milk fat globule membrane (MFGM).

Regulatory News

Oleic acid CHD claims success: US FDA approves qualified claim petition on high level foods 

20 Nov 2018 --- The US Food and Drug Administration (FDA) has responded positively to a petition for a new qualified health claim for edible oils containing oleic acid. As a result, products with an oleic acid content upward of 70 percent, such as certain olive, canola and sunflower oils, can be labeled as carrying cardiovascular benefits, but only when replacing heart-damaging saturated fat.

Health & Nutrition News

Weekly Roundup: DSM enters Japanese partnership on healthy aging, Croda expands with Marine Biotechnology innovation center

16 Nov 2018 --- In nutrition news this week, Croda opened a new Center of Innovation for Marine Biotechnology and DSM entered a collaboration on the development of services in nutritional rehabilitation and disease prevention in Japan. Lonza and Sartorius Stedim Biotech (SSB) are modifying their current agreement for the supply of cell culture media by mutual accord. Lastly, Gelita recently hosted a US symposium called, “The Sounds of Health and Nutrition,” which aimed to offer inspiration for market opportunities in the global health and nutrition marketplace.

Food Ingredients News

Diabetes and cardiovascular disease top the list of health fears for older men, Lycored reveals

13 Nov 2018 --- Diabetes and cardiovascular disease are the most common health concerns for older men in the west, a new survey by wellness company Lycored has revealed. The research also indicates that  US men are more worried about heart disease than they are about cancer.

Health & Nutrition News

Weekly Roundup: CJ CheilJedang expands Indonesia plant, Valensa hosts expert panel on saw palmetto

09 Nov 2018 --- This week in nutrition, CJ CheilJedang has expanded its Indonesia Jombang plant with a new production line, while Advanced Organic Materials is expanding its manufacturing operations into Spain. OmniActive Health Technologies CurcuWIN and Lutemax 2020 both gained US Pharmacopeia (USP) verification, and Valensa International appointed Sendhil Pani to lead its microalgae market expansion. Valensa also hosted an expert panel yesterday to examine the damage to saw palmetto extract’s sustainability following recent hurricane damage in the Florida area.

More Articles
URL : http://www.nutritioninsight.com:80/news/ultra-low-cholesterol-poses-no-safety-issues-analysis-suggests.html